Vijay Kumar
Stock Analyst at Evercore ISI Group
(3.28)
# 1,046
Out of 4,761 analysts
194
Total ratings
49.11%
Success rate
1.64%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Maintains: In-Line | $75 → $73 | $73.30 | -0.41% | 11 | Feb 12, 2025 | |
| MTD Mettler-Toledo International | Maintains: Outperform | $1,450 → $1,475 | $1,286.54 | +14.65% | 9 | Feb 10, 2025 | |
| HOLX Hologic | Maintains: In-Line | $76 → $73 | $64.49 | +13.20% | 13 | Feb 6, 2025 | |
| AZTA Azenta | Maintains: In-Line | $50 → $52 | $44.75 | +16.20% | 6 | Feb 6, 2025 | |
| JBHT J.B. Hunt Transport Services | Maintains: Outperform | $207 → $202 | $167.71 | +20.45% | 6 | Jan 17, 2025 | |
| NVCR NovoCure | Upgrades: Outperform | $18 → $30 | $22.09 | +35.81% | 11 | Dec 2, 2024 | |
| EXAS Exact Sciences | Maintains: Outperform | $80 → $60 | $49.26 | +21.80% | 3 | Nov 6, 2024 | |
| USB U.S. Bancorp | Maintains: In-Line | $51 → $54 | $45.87 | +17.72% | 4 | Oct 30, 2024 | |
| SYK Stryker | Maintains: Outperform | $380 → $384 | $382.78 | +0.32% | 9 | Oct 30, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $630 → $620 | $532.55 | +16.42% | 10 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $475 → $490 | $591.79 | -17.20% | 11 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $19 → $25 | $15.75 | +58.73% | 7 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $113 → $110 | $104.83 | +4.93% | 12 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $374.82 | -5.29% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $41.31 | +35.56% | 5 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $141.70 | +12.91% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $104 | $89.94 | +15.63% | 4 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $102 | $91.09 | +11.98% | 3 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $58 | $42.71 | +35.80% | 3 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $278 | $210.23 | +32.24% | 2 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $90 | $104.49 | -13.87% | 5 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $227.43 | +27.51% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $124 | $134.92 | -8.09% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $135 → $145 | $135.37 | +7.11% | 2 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4.5 → $5 | $3.80 | +31.58% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $45 | $33.82 | +33.06% | 6 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $17.30 | +56.07% | 10 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $195 → $175 | $94.20 | +85.77% | 6 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $88 → $125 | $113.84 | +9.80% | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.03 | +579.61% | 1 | May 31, 2022 |
Edwards Lifesciences
Feb 12, 2025
Maintains: In-Line
Price Target: $75 → $73
Current: $73.30
Upside: -0.41%
Mettler-Toledo International
Feb 10, 2025
Maintains: Outperform
Price Target: $1,450 → $1,475
Current: $1,286.54
Upside: +14.65%
Hologic
Feb 6, 2025
Maintains: In-Line
Price Target: $76 → $73
Current: $64.49
Upside: +13.20%
Azenta
Feb 6, 2025
Maintains: In-Line
Price Target: $50 → $52
Current: $44.75
Upside: +16.20%
J.B. Hunt Transport Services
Jan 17, 2025
Maintains: Outperform
Price Target: $207 → $202
Current: $167.71
Upside: +20.45%
NovoCure
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $22.09
Upside: +35.81%
Exact Sciences
Nov 6, 2024
Maintains: Outperform
Price Target: $80 → $60
Current: $49.26
Upside: +21.80%
U.S. Bancorp
Oct 30, 2024
Maintains: In-Line
Price Target: $51 → $54
Current: $45.87
Upside: +17.72%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $380 → $384
Current: $382.78
Upside: +0.32%
Thermo Fisher Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $630 → $620
Current: $532.55
Upside: +16.42%
Oct 18, 2024
Maintains: In-Line
Price Target: $475 → $490
Current: $591.79
Upside: -17.20%
Oct 15, 2024
Upgrades: Outperform
Price Target: $19 → $25
Current: $15.75
Upside: +58.73%
Oct 1, 2024
Maintains: In-Line
Price Target: $113 → $110
Current: $104.83
Upside: +4.93%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $374.82
Upside: -5.29%
Oct 1, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $41.31
Upside: +35.56%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $141.70
Upside: +12.91%
Oct 1, 2024
Maintains: Outperform
Price Target: $100 → $104
Current: $89.94
Upside: +15.63%
Oct 1, 2024
Maintains: Outperform
Price Target: $98 → $102
Current: $91.09
Upside: +11.98%
Oct 1, 2024
Maintains: Outperform
Price Target: $62 → $58
Current: $42.71
Upside: +35.80%
Oct 1, 2024
Maintains: Outperform
Price Target: $275 → $278
Current: $210.23
Upside: +32.24%
Oct 1, 2024
Maintains: Outperform
Price Target: $82 → $90
Current: $104.49
Upside: -13.87%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $227.43
Upside: +27.51%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $124
Current: $134.92
Upside: -8.09%
Oct 1, 2024
Maintains: In-Line
Price Target: $135 → $145
Current: $135.37
Upside: +7.11%
Aug 7, 2024
Maintains: In-Line
Price Target: $4.5 → $5
Current: $3.80
Upside: +31.58%
Jul 2, 2024
Maintains: Outperform
Price Target: $46 → $45
Current: $33.82
Upside: +33.06%
Jul 2, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $17.30
Upside: +56.07%
Jun 11, 2024
Maintains: Outperform
Price Target: $195 → $175
Current: $94.20
Upside: +85.77%
Jan 4, 2024
Upgrades: Outperform
Price Target: $88 → $125
Current: $113.84
Upside: +9.80%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.03
Upside: +579.61%